Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dafna Yahav

Showing results (201-210 of 231) with videos related to

Pageof 24
Sort By:
The Journal of Infection|October 7, 2024
Recurrent Clostridioides difficile infections in solid organ transplant recipients: The international CALIPSO studyGiusy Tiseo, Dafna Yahav, Alaa Atamna, et al.
BMJ Open|December 8, 2025
Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCENick Daneman, Jennie Johnstone, Todd C Lee, et al.
Microbiology Spectrum|May 23, 2023
Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumanniiHadas Kon, Amichay Hameir, Amir Nutman, et al.
NEJM Evidence|March 24, 2026
West Nile Virus-Neutralizing Plasma for West Nile Virus DiseaseGili Regev-Yochay, Noam Barda, Yonatan Shusterman, et al.
BMJ Open|April 22, 2016
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocolYaakov Dickstein, Leonard Leibovici, Dafna Yahav, et al.
The Journal of Antimicrobial Chemotherapy|January 27, 2022
Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistanceSammy Frenk, Elizabeth Temkin, Mor N Lurie-Weinberger, et al.
Gerontology|October 23, 2022
External Validity of a Randomized Controlled Trial on Duration of Antibiotics for the Treatment of Gram-Negative BacteremiaAdi Turjeman, Fidi Koppel, Erica Franceschini, et al.
The Lancet. Infectious Diseases|February 20, 2018
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trialMical Paul, George L Daikos, Emanuele Durante-Mangoni, et al.
Trials|February 11, 2025
Statistical documentation for multi-disease, multi-domain platform trials: our experience with the Staphylococcus aureus Network Adaptive Platform trialRobert K Mahar, Anna McGlothlin, Michael Dymock, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|August 26, 2024
Initial empirical antibiotic therapy in kidney transplant recipients with pyelonephritis: A global survey of current practice and opinions across 19 countries on six continentsJulien Coussement, Shyam B Bansal, Anne Scemla, et al.
Pageof 24

Showing results (201-210 of 231) with videos related to

Sort By:
Pageof 24
The Journal of Infection|October 7, 2024
Recurrent Clostridioides difficile infections in solid organ transplant recipients: The international CALIPSO studyGiusy Tiseo, Dafna Yahav, Alaa Atamna, et al.
BMJ Open|December 8, 2025
Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCENick Daneman, Jennie Johnstone, Todd C Lee, et al.
Microbiology Spectrum|May 23, 2023
Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumanniiHadas Kon, Amichay Hameir, Amir Nutman, et al.
NEJM Evidence|March 24, 2026
West Nile Virus-Neutralizing Plasma for West Nile Virus DiseaseGili Regev-Yochay, Noam Barda, Yonatan Shusterman, et al.
BMJ Open|April 22, 2016
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocolYaakov Dickstein, Leonard Leibovici, Dafna Yahav, et al.
The Journal of Antimicrobial Chemotherapy|January 27, 2022
Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistanceSammy Frenk, Elizabeth Temkin, Mor N Lurie-Weinberger, et al.
Gerontology|October 23, 2022
External Validity of a Randomized Controlled Trial on Duration of Antibiotics for the Treatment of Gram-Negative BacteremiaAdi Turjeman, Fidi Koppel, Erica Franceschini, et al.
The Lancet. Infectious Diseases|February 20, 2018
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trialMical Paul, George L Daikos, Emanuele Durante-Mangoni, et al.
Trials|February 11, 2025
Statistical documentation for multi-disease, multi-domain platform trials: our experience with the Staphylococcus aureus Network Adaptive Platform trialRobert K Mahar, Anna McGlothlin, Michael Dymock, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|August 26, 2024
Initial empirical antibiotic therapy in kidney transplant recipients with pyelonephritis: A global survey of current practice and opinions across 19 countries on six continentsJulien Coussement, Shyam B Bansal, Anne Scemla, et al.
Pageof 24